Reuters logo
BRIEF-Cascadian Therapeutics amends HER2CLIMB phase 2 trial of tucatinib in metastatic HER2-positive breast cancer to support registration
December 7, 2016 / 12:45 PM / a year ago

BRIEF-Cascadian Therapeutics amends HER2CLIMB phase 2 trial of tucatinib in metastatic HER2-positive breast cancer to support registration

Dec 7 (Reuters) - Cascadian Therapeutics Inc :

* Cascadian Therapeutics Inc - updated data from phase 1b triplet combination trial at sabcs

* Cascadian Therapeutics Inc - her2climb amended to single pivotal randomized trial to assess progression-free survival (pfs) as primary endpoint

* Cascadian Therapeutics Inc- HER2CLIMB is currently enrolling in United States and Canada and is expected to expand into Europe, Australia and Israel

* Cascadian Therapeutics - after meeting with FDA, amended HER2CLIMB phase 2 clinical trial of tucatinib by increasing sample size

* Updated phase 1b trial results for triplet combination show that combination continues to be well tolerated

* Cascadian Therapeutics amends HER2CLIMB phase 2 trial of tucatinib in metastatic her2-positive breast cancer to support registration Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below